BioCryst Pharmaceuticals provided a corporate update.

Jon Stonehouse, President and Chief Executive Officer of BioCryst, said: “Our third quarter performance continues to build on the outstanding year we are having. As we look ahead, we see new opportunities for younger children to benefit from Orladeyo.”

Charlie Gayer, Chief Commercial Officer of BioCryst, said: “The real-world efficacy and convenience patients and physicians are experiencing with Orladeyo are driving accelerated momentum.”

(Source: BioCryst)